Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:businessModel |
private
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focus |
neurological disorders
medical aesthetics neurotoxins |
| gptkbp:founded |
1908
|
| gptkbp:founder |
gptkb:Friedrich_Merz
|
| gptkbp:headquarters_location |
gptkb:Frankfurt_am_Main
|
| https://www.w3.org/2000/01/rdf-schema#label |
Merz Pharma
|
| gptkbp:industry |
aesthetics
neurology pharmaceuticals |
| gptkbp:keyPerson |
gptkb:Philip_Burchard
|
| gptkbp:numberOfEmployees |
over 3,000
|
| gptkbp:operatesIn |
global
|
| gptkbp:products |
gptkb:Cerebrolysin
gptkb:Radiesse gptkb:Xeomin gptkb:Belotero |
| gptkbp:subsidiary |
gptkb:Merz_Aesthetics
gptkb:Merz_Therapeutics |
| gptkbp:website |
https://www.merz.com/
|
| gptkbp:bfsParent |
gptkb:Akatinol
gptkb:Bioform gptkb:Xeomin gptkb:Merz |
| gptkbp:bfsLayer |
7
|